Pyare Richa, Ganvir Amol, Goyal Shina, Rao Chetan, Dutta Majumder Parthopratim
Clinical Fellow Department of Uvea & Intraocular Inflammation, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
Resident, Sankara Nethralaya, Chennai, India.
Ocul Immunol Inflamm. 2023 Apr;31(3):635-637. doi: 10.1080/09273948.2022.2042318. Epub 2022 Feb 28.
To describe a case of retinal vascular occlusion and cerebrovascular accident following axitinib therapy.
A retrospective chart review.
A 65-year-old gentleman with a history of renal cell carcinoma and subsequent metastases to the brain was on axitinib at an oral daily dose of 10 mg. The patient reported a loss in vision in the right, followed by the left eye, and suffered an episode of cerebrovascular accident. Retinal examination revealed right eye optic nerve pallor with sclerosed vessels, possibly sequelae of central retinal vein occlusion, and left eye showed multiple retinal hemorrhages in all quadrants with macular edema, suggestive of central retinal vein occlusion. He was not a known hypertensive, his renal carcinoma was in remission, and his other systemic parameters were within acceptable limits.
Axitinib can cause retinal vein occlusions, and clinicians, both oncologists, and ophthalmologists need to be aware of this rare but potentially blinding side effect.
描述一例阿昔替尼治疗后发生视网膜血管阻塞和脑血管意外的病例。
进行回顾性病历审查。
一名65岁男性，有肾细胞癌病史并继发脑转移，正在服用阿昔替尼，每日口服剂量为10毫克。患者报告右眼视力丧失，随后左眼也出现视力丧失，并发生了一次脑血管意外。视网膜检查显示右眼视神经苍白，血管硬化，可能是视网膜中央静脉阻塞的后遗症，左眼各象限有多处视网膜出血并伴有黄斑水肿，提示视网膜中央静脉阻塞。他不是已知的高血压患者，他的肾癌处于缓解期，其他全身参数在可接受范围内。
阿昔替尼可导致视网膜静脉阻塞，肿瘤学家和眼科医生等临床医生需要意识到这种罕见但可能致盲的副作用。
